Clinical Handbook of Psychotropic Drugs for Children and Adolescents
New edition released May 2023Quick and comprehensive information on psychotropic drugs for children and adolescents.Accurate and up-to-dateSpecific to children and adolescentsCharts and tables help decision-makingIcons and full colorMore about this bookMany psychotropic drugs are used to treat childhood and adolescent mental illness on the basis of efficacy in adults, despite not being currently approved for use in the young. The lack of approval does not necessarily reflect lack of safety or efficacy, but it does reflect a lack of controlled studies.The Clinical Handbook of Psychotropic Drugs for Children and Adolescents is a unique resource to help you make the right choice for younger patients:Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment optionsSuccinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, nursing implications, and much more – all you need to know for each class of drugPotential interactions and side effects summarized in comparison chartsWith instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seekClearly written patient and caregiver information sheets for download as printable PDF filesThis book is a must for all mental health professionals working with children and adolescents who need an up-to-date, easy-to use, comprehensive summary of all the most relevant information about psychotropic drugs.Watch an interview with Dean Elbe about the new editionNew in this edition:Drugs for ADHD thoroughly revised and updatedAntipsychotics with many changes and additions, including fully revised lab tests/monitoringAntidepressants fully revised, including new sections on irreversible MAO-B inhibitor and serotonin modulator and stimulator (SMS), revised frequency of adverse effects table and switching strategies recommendationsHypnotics completely revisedMood stabilizers fully revised and a new toxicity comparison table addedDrugs of abuse and treatment of substance use disorders comprehensively revisedNew unapproved treatments with significant updates, including: anti-inflammatories and NMDA agents in anxiety/OCD, cannabis use disorder, and irritability of autism New agents include: Third generation antipsychotics brexpiprazole and cariprazine, orexin receptor antagonist suvorexant, selective melatonin agonist tasimelteon, serotonin modulator and stimulator vortioxetineNew formulations and trade names include: Adasuve, Alprazolam Intensol, Aptensio XR, Aristada, Belbuca, Belsomra, Brintellix, Bunavail, Cotempla XR-ODT, Dyanavel XR, Eldepryl, EMSAM, Evekeo, Hemangeol, Hetlioz, Innopran XL, Invega Trinza, Khedezla, Metadol-D, Mydayis, NyQuil, Quillichew ER, Quillivant XR, Rexulti, Tegretol (liquid), Trintellix, Versacloz, Vraylar, Zelapar, ZenzediTo the patient and caregiver information sheetsDo you want print and online? Deal with adults and children? Then combine CHPD publications and save. Click here for more information.]]